Favorable response to erlotinib in a lung adenocarcinoma with both epidermal growth factor receptor exon 19 deletion and K-ras G13D mutations

Journal of Clinical Oncology

Volumn 28, Issue 7, 2010, Pages

  Lee, Chun Nin ^a   Chen, Hsiang Yin ^b   Liu, H Eugene ^b  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE; K RAS PROTEIN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; RAS PROTEIN;

ADULT; ARTICLE; BRAIN METASTASIS; BRAIN RADIATION; CANCER GROWTH; CANCER RADIOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG RESPONSE; EXON; FEMALE; GENE DELETION; GENE MUTATION; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LUNG ADENOCARCINOMA; LUNG BIOPSY; PRIORITY JOURNAL; SPINE METASTASIS; ADENOCARCINOMA; GENETICS; LUNG TUMOR; MIDDLE AGED; MUTATION;

ADENOCARCINOMA; EXONS; FEMALE; GENE DELETION; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; QUINAZOLINES; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 77949885180     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.24.0747     Document Type: Article

References (8)

1. Ding L, Getz G, Wheeler DA, et al: Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455:1069-1075, 2008
2. Linardou H, Dahabreh IJ, Kanaloupiti D, et al: Assessment of somatic K-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: A systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9:962-972, 2008
3. Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306-13311, 2004 (Pubitemid 39209661)
4. Huang CL, Taki T, Adachi M, et al: Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer. Int J Oncol 12:553-563, 1998 (Pubitemid 28097282)
5. Pao W, Wang TY, Riely GJ, et al: KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2:e17, 2005
6. Zhu JQ, Zhong WZ, Zhang GC, et al: Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals. Cancer Lett 265:307-317, 2008
7. Guerrero S, Casanova I, Farre L, et al: K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res 60:6750-6756, 2000
8. Hung KS, Lee CN, Liu HE: Rapid detection of hotspot mutations in epidermal growth factor receptor by polymerase chain reaction facilitates the management of non-small cell lung cancer. J Thorac Oncol 3:1202-1203, 2008